BJMO - volume 12, issue 8, december 2018
Tom Feys MBA, MSc
The introduction of immune checkpoint inhibitors and the combined use of BRAF and MEK inhibitors dramatically changed the treatment landscape of advanced melanoma over the last decade. The success of these agents in the advanced setting formed the basis to also evaluate these drugs in less advanced disease stages. During ESMO 2018 updates were given on the adjuvant use of dabrafenib and trametinib in resected stage III melanoma patients. In addition to this, results were presented on the use of immune checkpoint inhibitors in the neo-adjuvant setting. In the advanced melanoma setting, the most important data came from the four-year survival update of the CheckMate 067 trial and the presentation of the Keynote-022 study, in which the immune checkpoint inhibitor pembrolizumab was used in combination with dabrafenib and trametinib in the first-line treatment of BRAF-mutation positive advanced melanoma.
Read moreBJMO - volume 12, issue 7, november 2018
H. Van Poppel MD, PhD
At the occasion of the Annual Congress of the European Association of Urology (EAU), a number of new trial protocols with new immuno-oncology drugs were presented for bladder and renal cancer next to the results of studies on adjuvant and neo-adjuvant chemotherapy for upper tract transitional cell carcinoma. In prostate cancer, the value of prostate-specific antigen screening and multiparametric MRI at first diagnosis was investigated, and the results of clinical trials with enzalutamide and apalutamide were reported.
(BELG J MED ONCOL 2018;12(7):339–341)
Read moreBJMO - volume 12, issue 5, september 2018
W. Lybaert MD, T. Vandamme MD, PhD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD
March 7-9, 2018, Barcelona, Spain.
(BELG J MED ONCOL 2018:12(5):252–262)
Read moreBJMO - volume 12, issue 4, august 2018
J. Vansteenkiste MD, PhD, C. Dooms MD, PhD
This article will briefly discuss the top stories in the field of respiratory oncology presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO). For a complete overview of abstracts we refer to the official meeting website: https://am.asco.org.
Read moreBJMO - volume 12, issue 4, august 2018
P. Specenier MD, PhD
This article will summarize the key data in the field of head and neck cancer presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read moreBJMO - volume 12, issue 4, august 2018
F.P. Duhoux MD, PhD
At ASCO 2018, the results of several anticipated studies were presented. While most of these studies were thought provoking, many results left practicing oncologists a little bit disoriented. How to translate these data in clinical practice?
Read moreBJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, PhD, L. Triest MD, J. Van den Brande MD, K. Papadimitriou MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read more
Top
